Kolon TissueGene Doses First Patient in U.S. Phase III Clinical Trial
![Kolon TissueGene homepage screenshot](https://www.biolifesolutions.com/wp-content/uploads/2022/11/Screen-Shot-2018-12-03-at-12.37.24-PM.png)
On November 21, 2018, BioLife’s customer Kolon TissueGene, Inc., a leader in advanced cell and gene therapies, announced that it has dosed its first patient in its pivotal US Phase III clinical trials for Invossa, a cell and gene therapy in development for knee osteoarthritis (OA). “This is an exciting step for Kolon TissueGene as we […]